Department of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.
Cancer Biomark. 2018;23(1):61-65. doi: 10.3233/CBM-181309.
Interleukin-33 (IL-33) has been recently discovered as an influential factor in the process of tumor immunity, and is presented in cancer pathogenesis.
This study aimed to determine the serum levels of IL-33 in patients with benign and malignant Salivary gland tumors (SGTs).
This descriptive cross-sectional study was performed on 47 samples of malignant SGTs including 18 mucoepidermoid carcinoma (MEC), 8 adenoid cystic carcinoma (ADCC), 21 malignant mixed tumor (MMT), and 14 benign pleomorphic adenoma (PA). A control group was considered consisting of 28 healthy subjects. The serum level of IL-33 was measured by using sandwich ELISA method. The data were statistically analyzed through Kruskal-Wallis and Mann-Whitney tests.
The median concentration of IL-33 was 6.91 in malignant, 5.14 in benign, and 5.01 in healthy cases, with a statistically significant difference (P= 0.001). The median serum levels of IL-33 increased significantly in ADCC (7.15), MEC (7.03), and MMT (6.91) compared with the control group (5.01) (P< 0.05). The mean rank of MEC was significantly higher than PA (P= 0.01). IL-33 concentration was positively and significantly correlated with the tumor stage (P= 0.02) and tumor size (P= 0.03).
IL-33 could be suggested as a novel biomarker to distinguish different types of SGTs.
白细胞介素-33 (IL-33) 最近被发现是肿瘤免疫过程中的一个重要因素，并存在于癌症发病机制中。
本研究旨在测定良性和恶性涎腺肿瘤 (SGT) 患者的血清 IL-33 水平。
本研究为描述性的病例对照研究，共纳入 47 例恶性 SGT 患者样本，包括 18 例黏液表皮样癌 (MEC)、8 例腺样囊性癌 (ADCC)、21 例恶性混合瘤 (MMT) 和 14 例良性多形性腺瘤 (PA)。对照组包括 28 例健康受试者。采用夹心 ELISA 法检测血清 IL-33 水平。采用 Kruskal-Wallis 和 Mann-Whitney 检验对数据进行统计学分析。
恶性组、良性组和对照组的 IL-33 中位数浓度分别为 6.91、5.14 和 5.01，差异有统计学意义 (P=0.001)。ADCC (7.15)、MEC (7.03) 和 MMT (6.91) 组的血清 IL-33 水平明显高于对照组 (5.01) (P<0.05)。MEC 组的平均秩显著高于 PA 组 (P=0.01)。IL-33 浓度与肿瘤分期 (P=0.02) 和肿瘤大小 (P=0.03) 呈正相关。
IL-33 可能是鉴别不同类型 SGT 的新型生物标志物。
